Radical enhancements for cognition or longevity will likely be adopted by healthy people only after they are first developed and FDA-approved as therapies for specific diseases, like Alzheimer's. Competitive pressures will then drive widespread use, similar to obesity drugs.

Dr. Marson draws a clear ethical line between somatic edits (in an individual's non-reproductive cells) and germline edits (in sperm, eggs, or embryos). He believes we should not introduce heritable genetic changes, citing concerns about losing human diversity through genetic "fads" and unforeseen consequences.

For gene editing to achieve its potential, companies must solve an economic problem, not just a scientific one. The key is developing a manufacturing system that dramatically lowers costs, making one-time cures for the "long tail" of rare mutations financially viable and accessible.

To normalize the ethically fraught practice of embryo gene editing, startups like Preventive are shifting the narrative from just curing disease to radical cost reduction. They claim editing embryos could cost $5,000, a fraction of the $2 million price tag for current adult gene therapies.

The commercial advantage of one-time CRISPR/Cas9 therapies is shrinking. Advancements in RNA modalities like siRNA now offer durable, long-lasting effects with a potentially safer profile. This creates a challenging risk-reward calculation for permanent gene edits in diseases where both technologies are applicable, especially as investor sentiment sours on CRISPR's long-term safety.

Gene editing pioneer David Liu is developing a platform that could treat multiple, unrelated genetic diseases with a single therapeutic. By editing tRNAs to overcome common nonsense mutations, one therapy could address a wide range of conditions, dramatically increasing scalability and reducing costs.

George Church predicts that reversing aging via somatic gene therapy will be the first truly mainstream genetic enhancement. Since aging will affect 90% of the population, therapies that restore youthful function in the elderly will have a massive impact and widespread adoption, becoming the "GLP-1 moment" for gene editing.

George Church envisions a future where, in emergencies, millions of barcoded gene therapies could be tested simultaneously in one patient. This approach combines high-throughput synthesis with in-vivo testing to achieve nearly 100% accuracy by using a real human biological system.

George Church argues that the primary barrier to advancing multiplex gene editing wasn't a specific technological breakthrough like CRISPR, but rather the imagination to find medically and ecologically significant applications for pre-existing capabilities.